Compare DexCom, Inc. (DXCM) vs ON Holding AG (ONON) Price & Performance

DXCM trades at $90.23, up 2.94% today and near its 52-week high, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.70 versus $0.61 expected, and raised full-year guidance. Revenue growth remains robust at 13% year-over-year, supported by G7 system adoption and international expansion. Profit margins improved, with net income margin reaching 20.12% in 2025. Analyst sentiment is overwhelmingly positive, with 80% buy ratings.

The outlook for DXCM is favorable due to sustained demand for continuous glucose monitors and strategic initiatives like 'Road to 100'. Key risks include competitive pressures, regulatory scrutiny, and valuation multiples above industry averages. The stock's current price is slightly above the consensus target of $88.65, suggesting near-term consolidation may occur before further upside.

ONON stock plunged 19.93% to $31.05 after Q2 2026 results, driven by a revenue miss and lowered full-year growth guidance. Despite beating EPS estimates in recent quarters, the company faces wholesale channel softness and cautious consumer spending. Technical indicators are bearish, with the price near key support at $30, while fundamentals show strong profitability margins and positive cash flow trends. Analyst sentiment remains largely bullish with a $52.86 consensus target, but near-term volatility persists.

The outlook is mixed: long-term growth potential exists via direct-to-consumer strength and margin expansion, but investors face risks from guidance uncertainty and competitive pressures. The sharp sell-off may present a buying opportunity for patient investors, though volatility could continue until wholesale trends stabilize.